Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Sellas Life Sciences Group Inc SLS

Healthcare Biotechnology

SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of novel therapeutics for a range of cancer indications. The Company's product candidates, galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9), inhibitor... see more

Add To Watchlist

Recent & Breaking News (NDAQ:SLS)

SELLAS Life Sciences Provides Business Update and Reports Second Quarter 2018 Financial Results

GlobeNewswire August 15, 2018

SELLAS To Present Data from Phase 2b Trial of NeuVax + Herceptin® at Upcoming European Society for Medical Oncology (ESMO) 2018 Meeting

GlobeNewswire July 23, 2018

SELLAS Receives Fast Track Designation from FDA for Galinpepimut-S for the Treatment of Patients with Multiple Myeloma

GlobeNewswire July 20, 2018

SELLAS Life Sciences Announces Closing of $24.2 Million Public Offering

GlobeNewswire July 16, 2018

SELLAS Life Sciences Announces Pricing of Upsized $24.2 Million Public Offering

GlobeNewswire July 12, 2018

SELLAS Life Sciences Announces Proposed Public Offering of Common Stock

GlobeNewswire June 26, 2018

SELLAS Life Sciences Presents Interim Phase 1 Clinical Data of Galinpepimut-S (GPS) in Combination with Nivolumab to Treat Wilms Tumor 1 Positive (WT1+) Ovarian Cancer Patients at ASCO 2018

GlobeNewswire June 4, 2018

26 Stocks Moving In Friday's Mid-Day Session

Benzinga.com June 1, 2018

Mid-Morning Market Update: Markets Open Higher; Abercrombie & Fitch Beats Q1 Expectations

Benzinga.com June 1, 2018

SELLAS Life Sciences Provides Clinical Update on Phase 2b NeuVax™ (nelipepimut-S) Study in Combination with Trastuzumab in HER2 1+/2+ Breast Cancer Patients

GlobeNewswire June 1, 2018

SELLAS Life Sciences to Present Phase 1/2 Clinical Data of Galinpepimut-S (GPS) in Ovarian Cancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

GlobeNewswire May 17, 2018

SELLAS Life Sciences Receives FDA Orphan Drug Designation for Galinpepimut-S (GPS) for Treatment of Multiple Myeloma (MM)

GlobeNewswire May 9, 2018

SELLAS Life Sciences Completes Second Tranche of $10,700,000 Private Placement

GlobeNewswire May 2, 2018

SELLAS Life Sciences Announces Appointment of Gene Mack as Chief Financial Officer & Treasurer

GlobeNewswire April 20, 2018

SELLAS Life Sciences Reports Corporate Highlights, Advancements for its Cancer Immunotherapy Pipeline and 2017 Financial Results

GlobeNewswire April 16, 2018

18 Stocks Moving In Wednesday's Pre-Market Session

Benzinga.com April 4, 2018

SELLAS Life Sciences Announces Positive Interim Data from Phase 2b NeuVax™ (nelipepimut-S) Clinical Trial in Combination with Herceptin® in HER2 1+/2+ Breast Cancer Patients

GlobeNewswire April 2, 2018

SELLAS Life Sciences Announces Appointment of Barbara A. Wood as Executive Vice President, General Counsel and Corporate Secretary

GlobeNewswire March 21, 2018

SELLAS Life Sciences’ Phase 2 Results for Galinpepimut-S in High-Risk Multiple Myeloma Presented at European Society for Blood and Marrow Transplantation Meeting

GlobeNewswire March 19, 2018

The Week Ahead In Biotech: Earnings, PDUFA Dates And More

Benzinga.com March 16, 2018